Bioalpha Holdings Berhad Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bioalpha Holdings Berhad.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth	18.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Can You Imagine How Bioalpha Holdings Berhad's (KLSE:BIOHLDG) Shareholders Feel About The 42% Share Price Increase?

Jan 20

How Much Is Bioalpha Holdings Berhad's (KLSE:BIOHLDG) CEO Getting Paid?

Nov 28

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioalpha Holdings Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KLSE:BIOHLDG - Analysts future estimates and past financials data (MYR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	82	-39	-2	3	N/A
6/30/2024	59	-37	-7	-3	N/A
3/31/2024	45	-32	2	6	N/A
12/31/2023	46	-42	-2	1	N/A
9/30/2023	40	-52	-6	0	N/A
6/30/2023	35	-56	-1	4	N/A
3/31/2023	35	-61	-12	-6	N/A
12/31/2022	36	-48	-11	-4	N/A
9/30/2022	38	-24	-12	-8	N/A
6/30/2022	59	-16	-16	-8	N/A
3/31/2022	82	-7	-16	-4	N/A
12/31/2021	97	-1	-20	-4	N/A
9/30/2021	100	-13	-22	-2	N/A
6/30/2021	78	-25	-23	-6	N/A
3/31/2021	55	-34	-21	-3	N/A
12/31/2020	36	-41	-19	-2	N/A
9/30/2020	40	-22	-10	11	N/A
6/30/2020	50	-8	-8	14	N/A
3/31/2020	58	2	-9	11	N/A
12/31/2019	64	8	-9	16	N/A
9/30/2019	62	9	-16	8	N/A
6/30/2019	65	10	-17	13	N/A
3/31/2019	70	12	-15	14	N/A
12/31/2018	70	12	-15	10	N/A
9/30/2018	72	13	-8	12	N/A
6/30/2018	66	12	N/A	12	N/A
3/31/2018	60	10	N/A	11	N/A
12/31/2017	56	8	N/A	20	N/A
9/30/2017	52	8	N/A	10	N/A
6/30/2017	50	7	N/A	14	N/A
3/31/2017	49	6	N/A	11	N/A
12/31/2016	47	8	N/A	1	N/A
9/30/2016	41	8	N/A	14	N/A
6/30/2016	37	8	N/A	8	N/A
3/31/2016	33	7	N/A	6	N/A
12/31/2015	30	7	N/A	5	N/A
9/30/2015	28	6	N/A	6	N/A
6/30/2015	28	5	N/A	2	N/A
3/31/2015	28	7	N/A	7	N/A
12/31/2014	27	6	N/A	6	N/A
12/31/2013	25	6	N/A	5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BIOHLDG's forecast earnings growth is above the savings rate (3.6%).

Earnings vs Market: Insufficient data to determine if BIOHLDG's earnings are forecast to grow faster than the MY market

High Growth Earnings: Insufficient data to determine if BIOHLDG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BIOHLDG's revenue is forecast to grow faster than the MY market.

High Growth Revenue: Insufficient data to determine if BIOHLDG's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIOHLDG's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 13:15
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioalpha Holdings Berhad is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lee Fang Ng	CGS International
Michael Kokalari	Maybank Research Pte. Ltd.
Sze Tee	Maybank Research Pte. Ltd.

Bioalpha Holdings Berhad Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Bioalpha Holdings Berhad Provides Financial Guidance for the Year Ending December 31, 2020

Recent updates

Third quarter 2024 earnings released: RM0.004 loss per share (vs RM0.002 loss in 3Q 2023)

Second quarter 2024 earnings released: RM0.005 loss per share (vs RM0.003 loss in 2Q 2023)

Bioalpha Holdings Berhad Announces Resignation of Goh Siow Cheng as Executive Director

First quarter 2024 earnings released: RM0.005 loss per share (vs RM0.014 loss in 1Q 2023)

Bioalpha Holdings Berhad Announces Resignation of Datuk Chong Loong Men as Executive Director

Bioalpha Holdings Berhad, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: RM0.028 loss per share (vs RM0.038 loss in FY 2022)

New major risk - Share price stability

Third quarter 2023 earnings released: RM0.002 loss per share (vs RM0.005 loss in 3Q 2022)

New minor risk - Shareholder dilution

Bioalpha Holdings Berhad Appoints Tan Su Ning, Age 31, as Member of Risk Committee Directorate Independent and Non Executive, Date of Change 04 September 2023

Second quarter 2023 earnings released: RM0.003 loss per share (vs RM0.006 loss in 2Q 2022)

Less than half of directors are independent

Bioalpha Holdings Berhad Announces the Retirement of Encik Mohd Nasir Bin Abdullah as Independent and Non Executive Member of Remuneration Committee

First quarter 2023 earnings released: RM0.014 loss per share (vs RM0.003 loss in 1Q 2022)

Is Bioalpha Holdings Berhad (KLSE:BIOHLDG) A Risky Investment?

Full year 2022 earnings released: RM0.036 loss per share (vs RM0.001 loss in FY 2021)

Third quarter 2022 earnings released: RM0.005 loss per share (vs RM0.001 profit in 3Q 2021)

Does Bioalpha Holdings Berhad (KLSE:BIOHLDG) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: RM0.006 loss per share (vs RM0.001 profit in 2Q 2021)

Bioalpha Holdings Berhad Announces Cessation of Office of Dato' Norhalim Bin Yunus as Non Independent and Non Executive Member of Remuneration Committee

Is Bioalpha Holdings Berhad (KLSE:BIOHLDG) Using Debt Sensibly?

Bioalpha Holdings Berhad Announces Cessation of Tan Sri Dato' Dr. Jalaludin Bin Syed Salim as Independent and Non Executive Chairman of Nomination Committee

First quarter 2022 earnings: EPS and revenues miss analyst expectations

JOE Holding (M) Investment Limited acquired a 12.40% stake in Bioalpha Holdings Berhad (KLSE : BIOHLDG) for MYR 45 million.

Bioalpha Holdings Berhad, Annual General Meeting, Jun 28, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Bioalpha Holdings Berhad (KLSE:BIOHLDG) Is Using Debt Safely

Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2021 earnings released

First quarter 2021 earnings released: EPS RM0.001 (vs RM0.006 loss in 1Q 2020)

Why Bioalpha Holdings Berhad (KLSE:BIOHLDG) Could Be Worth Watching